368870-03-5

Basic information

• Product Name: 4-(1H-PYRAZOL-1-YL)BENZYLAMINE
• Synonyms: AKOS B014367;4-PYRAZOL-1-YL-BENZYLAMINE;4-(1-PYRAZOLYL)BENZYLAMINE;4-(1H-PYRAZOL-1-YL)BENZYLAMINE;ART-CHEM-BB B020480;ART-CHEM-BB B014367;BUTTPARK 98\50-46;CHEMBRDG-BB 4003287
• CAS NO: 368870-03-5
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 368870-03-5.mol

Chemical Properties

• Melting Point: 94-95°C
• Boiling Point: 307.1°Cat760mmHg
• Flash Point: 139.6°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 0.000738mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.89±0.10(Predicted)
• CAS DataBase Reference: 4-(1H-PYRAZOL-1-YL)BENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1H-PYRAZOL-1-YL)BENZYLAMINE(368870-03-5)
• EPA Substance Registry System: 4-(1H-PYRAZOL-1-YL)BENZYLAMINE(368870-03-5)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-41-37/38
• Safety Statements: 26-36/37/39-39
• RIDADR: 2735
• Hazardous Substances Data: 368870-03-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(1H-Pyrazol-1-yl)benzylamine is used as an anti-inflammatory and analgesic agent for its potential to alleviate pain and reduce inflammation. Its properties make it a promising candidate for the development of new medications to treat various conditions associated with pain and inflammation.
Used in Agrochemical Industry:
4-(1H-Pyrazol-1-yl)benzylamine is used as an insecticide and acaricide for its insecticidal and acaricidal properties, making it a potential candidate for use in pesticide formulations to control pests and mites in agriculture.
Used in Chemical Synthesis:
4-(1H-Pyrazol-1-yl)benzylamine is used as a building block in the synthesis of new organic compounds with diverse biological activities. Its versatile chemical structure allows for the development of a wide range of compounds with potential applications in various fields, including medicine, materials science, and environmental science.

InChI:InChI=1/C10H11N3/c11-8-9-2-4-10(5-3-9)13-7-1-6-12-13/h1-7H,8,11H2

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 25699-83-6 4-pyrazol-1-yl-benzonitrile 

Relevant articles and documents

PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS

The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: (I), where R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein.

Compounds and methods for inhibiting phosphate transport

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules

Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independe

PYRIDYLAMINOACETIC ACID COMPOUND

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl

1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS

The present invention relates to compound S of Formula (I).